Feasibility and ability of laparoscopy to predict respectability in ovarian cancer: Review article

Mohammed Abd El Rahman; Ahmed Magdy Mahmoud; Abd El Naser Abd El Gaber Ali; Hanan Mahmoud Fayed; Mostafa Mohammed Khodary

doi:10.53730/ijhs.v6nS7.12790

Authors

Mohammed Abd El Rahman Department of Obstetrics and Gynecology, Faculty of Medicine, South Valley University, Qena, Egypt
Ahmed Magdy Mahmoud
ahmedelmohandes88@yahoo.com
Department of Clinical and Chemical Pathology, Faculty of Medicine, South Valley University, Qena, Egypt
Abd El Naser Abd El Gaber Ali Department of Clinical and Chemical Pathology, Faculty of Medicine, South Valley University, Qena, Egypt
Hanan Mahmoud Fayed Department of Clinical and Chemical Pathology, Faculty of Medicine, South Valley University, Qena, Egypt
Mostafa Mohammed Khodary Department of Clinical and Chemical Pathology, Faculty of Medicine, South Valley University, Qena, Egypt

Keywords:

Laparoscopy, Chemotherapy, Adjuvant, Laparoscopes, Neoplasm

Abstract

Background: Epithelial ovarian cancer is one of the leading causes of death in gynecological malignancies and the seventh most common cancer in the world among women. Aim and objectives: The main aim of this study was to study the feasibility and ability of laparoscopy in predicting optimum respectability in cases of ovarian cancer. Conclusion: Laparoscopy has an effective feasibility and ability in predicting optimum respectability in cases of ovarian cancer. As laparoscopy before starting treatment was a reliable additional diagnostic tool in predicting result of PDS, this can prevent laparotomies. This will optimize treatment for the individual patient.

Downloads

Download data is not yet available.

References

● Alcázar JL, Caparros M, Arraiza M, Mínguez JÁ, Guerriero S, Chiva L, et al. Pre-operative assessment of intra-abdominal disease spread in epithelial ovarian cancer?: a comparative study between ultrasound and computed tomography. Int J Gynecol Cancer. 2019;227–33.

● Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007;107:99–106.

● American College of Radiology. ACR Appropriateness Criteria: Staging and Follow-up of Ovarian Cancer. Revised 2018 [Internet]. 2018;1– 12. Available from: https://acsearch.acr.org/docs/69504/Narrative/.

● Armstrong DK, Walker JL. Role of Intraperitoneal Therapy in the Initial Management of Ovarian Cancer. J Clin Oncol. 2019 Sep 20;37(27):2416-2419.

● Arora T, Mullangi S, Lekkala MR. Ovarian Cancer. Updated 2022 Jan 4. In: StatPearls Internet. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK567760/

● Babaier A, Ghatage P. Mucinous Cancer of the Ovary: Overview and Current Status. Diagnostics (Basel). 2020 Jan 19;10(1)

● Bendifallah S, Body G, Daraï E, Ouldamer L. Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: article drafted from the French Guidelines in Oncology entitled “Initial management of PA”. Gynecol Obstet Fertil Senol. 2019;47:134–54.

● Berek JS, Hacker NF (2014) Berek & Hacker’s gynecologic oncology, 6th edn. Wolters Kluwer Health, Philadelphia, Pennsylvania

● Brun JL, Rouzier R, Uzan S, Darai E. (2008). External validation of a laparoscopic‐based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score. Gynecologic Oncology;110(3):354‐9.

● Cui R, Wang Y, Li Y, Li Y. Clinical value of ROMA index in diagnosis of ovarian cancer: meta-analysis. Cancer Manag Res. 2019;11:2545–51.

● Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019 Mar 27;12(1):28.

● Earle CC, Schrag D, Neville BA, et al: Eﬀect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 98:172, 2066

● Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, et al. Laparoscopic surgical algorithm to triage the timing of tumor reductive surgery in advanced ovarian cancer. Obstet Gynecol. 2018;132:545–54.

● Gallotta V, Ghezzi F, Vizza E, Chiantera V, Ceccaroni M, Franchi M, et al. Laparoscopic staging of apparent early stage ovarian cancer: results of a large, retrospective, multi-institutional series. Gynecol Oncol. 2014 Dec;135(3):428-34.

● Gharib, M., El-Shoeiby, M., Metwally, N., & Rashid, Y. (2018). Epidemiology of ovarian cancer in Assiut Governorate, Egypt. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 7(11), 4575-4580.

● Hirabayashi S., Hibi K., Hotta Y., et al. Transumbilical single-port laparoscopic surgery for colorectal cancers: experience of 258 consecutive cases with rational manipulation of instrument for safety and benefit. Annals of Cancer Research and Therapy. 2016;24(1):7–11.

● Husain A, Chi DS, Prasad M, Abu-Rustum N, Barakat RR, Brown CL, et al. The role of laparoscopy in second-look evaluations for ovarian cancer. Gynecol Oncol 2001 Jan;80(1):44-7.

● Ibrahim AS, Seif-Eldin IA, Ismail K, Hablas A, Hussein H, Elhamzawy H. Cancer in Egypt, Gharbiah: Triennial Report of 2000-2002, Gharbiah Population-based Cancer Registry. Cairo: Middle East Cancer Consortium. 2007.

● Jiang Y., Song H., Wang R., Gu M., Sun J., Sha L. Data-centered runtime verification of wireless medical cyber-physical system. IEEE Transactions on Industrial Informatics. 2017;13(4):1900–1909.

● Kadhel P, Revaux A, Carbonnel M, Naoura I, Asmar J, Ayoubi J. (2019). An update on preoperative assessment of the resectability of advanced ovarian cancer. Hormone Molecular Biology and Clinical Investigation, 0(0), –.

● Khalique S, Hook JM, Ledermann JA. Maintenance therapy in ovarian cancer. Curr Opin Oncol. 2014 Sep;26(5):521-8.

● Khiewvan B, Torigian DA, Emamzadehfard S, Paydary K, Salavati A, Houshmand S, et al. An update on the role of PET/CT and PET/MRI in ovarian cancer. Eur J Nucl Med Mol Imaging. 2017;44:1079–91.

● Kong, Q., Wei, H., Zhang, J. et al. Comparison of the survival outcomes of laparoscopy versus laparotomy in treatment of early-stage ovarian cancer: a systematic review and meta-analysis. J Ovarian Res 14, 45 (2021).

● Kurman RJ, Shih IeM. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. Am J Pathol. 2016 Apr;186(4):733-47.

● Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014 Sep;6(5):229-39.

● Mancari R, Cutillo G, Bruno V, Vincenzoni C, Mancini E, Baiocco E, et al. Development of new medical treatment for epithelial ovarian cancer recurrence. Gland Surg. 2020 Aug;9(4):1149-1163.

● Manoharan D, Das CJ, Aggarwal A, Gupta AK. Diffusion weighted imaging in gynecological malignancies – present and future. World J Radiol. 2016;8:288.

● Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019; 11:287-299.

● Morgan RJ Jr, Armstrong DK, Alvarez RD, et al: Ovarian cancer, including fallopian tube cancer and primary peritoneal cancer, 3.2014. NCCN Clinical Practice Guidelines in Oncology. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed January 12, 2015.

● Mostafa MF, El-etreby N, Awad N. Retrospective analysis evaluating ovarian cancer cases presented at the Clinical Oncology Department, Alexandria University. Alexandria J Med. 2012;48:353-60.

● Nicolai N, Tarabelloni N, Gasperoni F, Catanzaro M, Stagni S, Torelli T, et al. Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center. J Urol. 2018 Mar;199(3):741-747.

● O’Shea A.S. (2022) Clinical Staging of Ovarian Cancer. In: Kreeger P.K. (eds) Ovarian Cancer. Methods in Molecular Biology, vol 2424. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1956-8_1

● Ohtani H., Maeda K., Nomura S., et al. Meta-analysis of robot-assisted versus laparoscopic surgery for rectal cancer. In Vivo (Athens, Greece) 2018;32(3):611–623.

● Palaia I, Tomao F, Sassu CM, Musacchio L, Benedetti Panici P. Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches. Onco Targets Ther. 2020;13:6109-6129.

● Paunovic V, Protrka Z, Ardalic D, Paunovic T. Usefulness of human epididymis protein 4 in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer. J BUON. 2017;22:29–33.

● PDQ Adult Treatment Editorial Board. PDQ Cancer Information Summaries Internet. National Cancer Institute (US); Bethesda (MD): May 20, 2021. Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®): Health Professional Version.

● Petrillo, M., Vizzielli, G., Fanfani, F., Gallotta, V., Cosentino, F., Chiantera, V., et al. (2015). Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept. Gynecologic oncology, 139(1), 5-9.

● Pignata S, Di Maio M, Gallo C, Perrone F. Carboplatin plus paclitaxel scheduling for advanced ovarian cancer - authors' reply. Lancet Oncol. 2014 Jun;15(7):e250-1.

● Prat J (2014) Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 124(1):1–5.

● Quirk JT, Natarajan N: Ovarian cancer incidence in the United States, 1992–1999. Gynecol Oncol 2005 97:519.

● Renjen PN, Chaudhari DM, Shilpi US, Zutshi D, Ahmad K. Paraneoplastic Cerebellar Degeneration Associated With Ovarian Adenocarcinoma: A Case Report and Review of Literature. Ann Indian Acad Neurol. 2018 Oct-Dec;21(4):311-314.

● Rosen DG, Yang G, Liu G, Mercado-Uribe I, Chang B, Xiao XS, et al. Ovarian cancer: pathology, biology, and disease models. Front Biosci (Landmark Ed). 2009 Jan 01;14:2089-102.

● Roze JF, Hoogendam JP, van de Wetering FT, Spijker R, Verleye L, Vlayen J, et al. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer. Cochrane Database Syst Rev. 2018;10:CD012567.

● Rutten H.S, van Meurs R, van de Vrie K.N, Gaarenstroom C.A, Naaktgeboren, T, van Gorp et al. (2017). Laparoscopy to predict the result of primary cytoreductive surgery in patients with advanced ovarian cancer: a randomized controlled trial, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 35, 613–621.

● Rutten M.J., Gaarenstroom, K.N., Van Gorp T. et al. Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study. BMC Cancer 12, 31 (2012).

● Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC, Sood AK, et al. (2010) Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol 116(2 Pt 1):269–273.

● Shankar K., Elhoseny M., Lakshmanaprabu S. K., et al. Optimal feature level fusion based ANFIS classifier for brain MRI image classification. Concurrency and Computation: Practice and Experience. 2020;32(1):p. 24887. doi: 10.1002/cpe.4887.

● Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan; 70(1):7-30.

● Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 2015 65(1):5.

● Smith CG. A Resident's Perspective of Ovarian Cancer. Diagnostics (Basel). 2017 Apr 27;7(2)

● Stewart, C., Ralyea, C., & Lockwood, S. (2019, April). Ovarian cancer: an integrated review. In Seminars in oncology nursing (Vol. 35, No. 2, pp. 151-156). WB Saunders.

● Suidan RS, Ramirez PT, Sarasohn DM, et al: A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol 2014 134(3):455.

● Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Get vaccinated when it is your turn and follow the local guidelines. International Journal of Health Sciences, 5(3), x-xv. https://doi.org/10.53730/ijhs.v5n3.2938

● Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, et al. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecol Oncol. 2017;145:27–31.

● van Meurs HS, Tajik P, Hof MH, Vergote I, Kenter GG, Mol BW, et al. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial. Eur J Cancer. 2013 Oct;49(15):3191-201.

● Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, et al. MRC CHORUS study investigators. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018 Dec;19(12):1680-1687.

● Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. (2010). Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine;363:943‐53.

● Vermeulen N, Abrao MS, Einarsson JI, et al. Endometriosis classification, staging and reporting systems: a review on the road to a universally accepted endometriosis classification. J Minim Invasive Gynecol. 2021. 28(11):1822-1848.

● von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, et al. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 Mar;144(3):459-467.

● Whitwell HJ, Worthington J, Blyuss O, Gentry-Maharaj A, Ryan A, Gunu R, et al. Improved early detection of ovarian cancer using longitudinal multimarker models. Br J Cancer. 2020 Mar;122(6):847-856.

● Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 Oct 01;34(28):3460-73.